Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis.

[1]  H. Thomsen.  Frequency of acute adverse events to a non-ionic low-osmolar contrast medium: the effect of verbal interview. , 1997, Pharmacology & toxicology.

[2]  J. Frisoli,et al.  Nephrotoxicity of high‐dose gadolinium compared with iodinated contrast , 1996, Journal of magnetic resonance imaging : JMRI.

[3]  J. Henriksen,et al.  Bidirectional peritoneal transport of albumin in continuous ambulatory peritoneal dialysis. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  L. Schad,et al.  Elimination of gadolinium-DTPA by peritoneal dialysis. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  P. Wedeking,et al.  Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.

[6]  T. Skotland,et al.  Detection and quantitation of gadolinium chelates in human serum and urine by high-performance liquid chromatography and post-column derivatization of gadolinium with Arsenazo III. , 1995, Journal of pharmaceutical and biomedical analysis.

[7]  P. Nilsson-ehle,et al.  Hemodialysis for elimination of the nonionic contrast medium iohexol after angiography in patients with impaired renal function. , 1995, Nephron.

[8]  K. Rootwelt,et al.  Pharmacokinetics of Gadodiamide Injection in Patients with Moderately Impaired Renal Function , 1994 .

[9]  J. Kaude,et al.  Dialysis is not indicated immediately after administration of nonionic contrast agents in patients with end-stage renal disease treated by maintenance dialysis. , 1994, AJR. American journal of roentgenology.

[10]  E. M. Watkin,et al.  Clearance of iopamidol, a non-ionic contrast medium, by CAPD in patients with end-stage renal failure. , 1992, The British journal of radiology.

[11]  T. Krahe,et al.  Pharmakokinetik von Gadolinium-DTPA bei dialysepflichtiger chronischer Niereninsuffizienz , 1992 .

[12]  G. Krestin,et al.  Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure. , 1992, Investigative radiology.

[13]  M. Bellin,et al.  Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure. , 1992, Magnetic resonance imaging.

[14]  G. Krestin,et al.  Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. , 1991, Investigative radiology.

[15]  S. Quay,et al.  A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. , 1991, Investigative radiology.

[16]  G. Schuhmann-Giampieri,et al.  Elimination of Gd-DTPA by means of hemodialysis. , 1990, European journal of radiology.

[17]  M. Espeland,et al.  A lack of coordination in the release of urinary lysosomal and brush border enzymes following renovascular surgery. , 1989, Clinica chimica acta; international journal of clinical chemistry.

[18]  P. Mueller,et al.  Alanine aminopeptidase in serum: automated optimized assay, and effects of age, sex, smoking, and alcohol consumption in a selected population. , 1987, Clinical chemistry.

[19]  K. Barry,et al.  Removal of iodinated contrast material by peritoneal dialysis. , 1974, Nephron.

[20]  J. Bröchner-Mortensen.  A simple method for the determination of glomerular filtration rate. , 1972, Scandinavian journal of clinical and laboratory investigation.